BREAST CANCER IN SITU

This adverse event was reported 0 times

BREAST CANCER IN SITU is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Estrogen [EPC] 618 0.0033
1 Progesterone [EPC] 33 0.0014
2 Provitamin D2 Compound [EPC] 33 0.0011
3 CCR5 Co-receptor Antagonist [EPC] 2 0.0009
4 Pyrethroid [EPC] 1 0.0006
5 Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] 4 0.0005
6 Interferon beta [EPC] 102 0.0005
7 Benzothiazole [EPC] 1 0.0004
8 Integrin Receptor Antagonist [EPC] 35 0.0004
9 Sympathomimetic-like Agent [EPC] 11 0.0003
See all drug classes enriched for association with BREAST CANCER IN SITU